30 closest matches · ranked by relevance
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Osteoporosis · Bone Diseases, Endocrine · Hyperparathyroidism
Primary: Participants With Dose Limiting Toxicity — 0; 2 participants
Hypoparathyroidism
Primary: The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24. — 2.5; 54.8 percentage of participants — p=<0.001
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
Osteoporosis
Primary: Procallagen-1 Amino-terminal Peptide (P1NP) — 32.54; 23.51; 60.67; 48.89 percentage change from baseline — p=<0.0005
Osteoporosis · Humoral Hypercalcemia of Malignancy · Hyperparathyroidism
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 2; 2 participants
Secondary Hyperparathyroidism
Primary: The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours — 40.6; 46.2; 39.8; 58.8 pg/ml — p=0.1
Hypoparathyroidism
Primary: Change From Baseline in Hypoparathyroidism Symptom Diary (HypoPT-SD) Symptom Subscale Score at Week 26 — -0.93; -1.46 score on a scale — p==0.003
Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 — -0.33; 2.96; 3.47; 4.97 percent change
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants
Osteoporosis
Primary: Bone Mineral Density (BMD): Examine the Pattern and Effect of BMD Changes at Hip and Spine Measured by DXA Every 6 Months. — 0.85; 0.84; 0.91 percent change
Hypoparathyroidism · Hypocalcemia · Autoimmune Polyendocrine Syndrome Type 1
Primary: Mean Serum Calcium in Children and Young Adults — 2.02; 1.88 mmol/liter — p=0.02
Moderate to Severe Secondary Hyperparathyroidism · Stage 5 Chronic Kidney Diseases
Primary: Mean Erythropoietin Dose Per Visit — 35.8; 22.2; 22.7; 4.7 µg
Osteoporosis · Bone Loss · Spinal Cord Injury
Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline
Hyperparathyroidism
Primary: Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration — 70.9; 32.5 pg/mL — p=0.049
Hypoparathyroidism
Primary: Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 8, Based on Investigator Prescribed Data. — 21.1; 26.1 percentage of participants — p=>0.999
Primary Hyperparathyroidism · Vitamin D Deficiency
Primary: Serum Parathyroid Hormone (PTH) Level
Post-Surgical Hypoparathyroidism
Primary: Percent Change in Fractional Excretion of Calcium (FECa) — -39 percentage of change
Chronic Allograft Nephropathy · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage…
Primary Hyperparathyroidism · Parathyroid Adenoma · Parathyroid Hyperplasia
Primary: Change in Lumbar Spine Bone Mineral Density — 0.030; 0.042; -0.016 g/cm^2 — p=< 0.00001
Vitamin D Deficiency · Primary Hyperparathyroidism · Hypercalcemia
Primary: Decrease in Preoperative P-PTH — -2.2; 0.2 pmol/l
Osteoporosis
Primary: Percentage Change in the Bone Formation Marker N-terminal Propeptides of Human Procollagen Type I (P1NP) From Baseline to End of Trial — 446.1; -6.2 percent change…
Primary Hyperparathyroidism
Primary: Change in Parathyroid Hormone Levels — 4.0; -3.7; 0.8 pg/mL — p=0.84
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]
Chronic Hypoparathyroidism · Hypoparathyroidism
Primary: Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 6 — -0.005 Millimole per liter (mmol/L)
Chronic Kidney Disease
Primary: The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels — 93; 57; 12; 45 participants
Hypophosphatemia, Familial · Hyperparathyroidism
Primary: Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement — 1223; 1449; 987; 1616 nlEq*26hr/ml — p=0.007
Hypoparathyroidism · Endocrine System Diseases · Parathyroid Diseases
Primary: Efficacy - Primary Endpoint During the Blinded Period — 50.0; 40.0; 60.0; 26.7 Percentage of participants — p== 0.2635